肺动脉高压的药物治疗进展

Abstract
Figure/Table
References (38)
Related Citation (15)

Download: PDF (0 KB) HTML (42 KB)
Export: BibTeX | EndNote (RIS)

Abstract Pulmonary arterial hypertension (PAH) is a life-threatening and fatal disease caused by a variety of known or unknown reasons that cause abnormally elevated pulmonary artery pressure,which has attracted widespread clinical attention.Clinical treatment drugs mainly include calcium channel blockers (CCB),prostacyclin,endothelin receptor antagonists (ETRA),phosphodiesterase inhibitors (PDE5i),guanylate cyclase (sGC) stimulators,etc.These drugs have been combined clinically to improve efficacy,reduce the incidence of adverse reactions.Although it can delay the course of the disease to a certain extent,improve the symptoms and prognosis,but there is no effective drug to reverse the progress of the disease.In recent years,studies have found that new targeted drugs such as vasoactive peptides(VIP),amino acid kinase inhibitors,immunosuppressive drugs,melatonin (MT),gene regulation drugs have shown a certain inhibitory effect on the progression of PAH.They are currently in the stage of research and development or clinical trials.This study introduces the pharmacological characteristics and research progress of the latest conventional drugs and new targeted drugs for the treatment of PAH.

Key words： Pulmonary arterial hypertension Medical treatment Targeted drugs Treatment progress

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Xiao-song

Cite this article:

YANG Xiao-song. Progress in drug treatment of pulmonary arterial hypertension[J]. 中国当代医药, 2021, 28(5): 37-41.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I5/37

[1]	卢一品，刘宏生.肺动脉高压的发病机制和药物治疗进展[J].临床心血管病杂志，2019，35（2）：109-112.
[2]	Simonneau G，Montani D，Celermajer DS，et al.Haemodynamic definitions and updated clinical classification of pulmonary hypertension[J].Eur Respir J，2019，53（1）：1 801 913.
[3]	Nair A.Pharmacologic therapy for pulmonary artery hypertension[J].Curr Opin Cardiol，2020，35（6）：643-656.
[4]	Halliday SJ，Hemnes AR.Identifying "super responders" in pulmonary arterial hypertension[J].Pulm Circ，2017，7（2）：300-311.
[5]	殷大伟，石涵宇，魏路清.前列环素类似物治疗肺动脉高压安全性与耐受性的Meta 分析[J].武警医学，2020，31（7）：553-556，560.
[6]	Keshavarz A，Kadry H，Alobaida A，et al.Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension[J].Expert Opin Drug Deliv，2020，17（4）：439-461.
[7]	郭宗儒.治疗肺动脉高压药物赛乐西帕[J].药学学报，2018，53（12）：2129-2134.
[8]	Parikh KS，Doerfler S，Shelburne N，et al.Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension[J].J Cardiovasc Pharmacol，2020，75（4）：299-304.
[9]	Chen XW，Zhai ZG，Huang K，et al.Bosentan therapy for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension：A systemic review and meta-analysis[J].Clin Respir J，2018，12（6）：2065-2074.
[10]	Nosrati M，Shahmirzadi NA，Afzali M，et al.Cost-utility analysis of Macitentan Vs.Bosentan in pulmonary atrial hypertension[J].J Family Med Prim Care，2020，9（7）：3634-3638.
[11]	Bhogal S，Khraisha O，Al Madani M，et al.Sildenafil for Pulmonary Arterial Hypertension[J].Am J Ther，2019，26（4）：e520-e526.
[12]	龙愉良，管丽华，周达新.慢性血栓栓塞性肺动脉高压的诊疗进展[J].中国临床新医学，2020，13（9）：863-868.
[13]	Tsai CH，Wu CK，Kuo PH，et al.Riociguat Improves Pulmonary Hemodynamics in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension[J].Acta Cardiol Sin，2020，36（1）：64-71.
[14]	Toxvig AK，Wehland M，Grimm D，et al.A focus on riociguat in the treatment of pulmonary arterial hypertension[J].Basic Clin Pharmacol Toxicol，2019，125（3）：202-214.
[15]	White RJ，Jerjes-Sanchez C，Bohns Meyer GM，et al.Combination therapy with oral treprostinil for pulmonary arterial hypertension.A double-blind placebo-controlled clinical trial[J].Am J Respir Crit Care Med，2020，201（6）：707-717.
[16]	程锦，孙闯，薛玉刚.利奥西呱联合西地那非治疗先天性心脏病合并肺动脉高压的临床疗效观察[J].现代医学，2020，48（4）：512-515.
[19]	张德振，韦安猛.波生坦联合他达拉非对肺动脉高压患者活动耐力和心功能的影响[J].中国临床医生杂志，2020，48（5）：566-569.
[17]	Galie N，Muller K，Scalise AV，et al.PATENT PLUS：a blinded，randomised and extension study of riociguat plus sildenafl in pulmonary arterial hypertension[J].Eur Respir J，2015，45（5）：1314-1322.
[18]	D′Alto M，Romeo E，Argiento P，et al.Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension：clinical and haemodynamic long-term efficacy[J].J Cardiovasc Med，2018，19（1）：12-17.
[20]	Dang ZC，Tang B，Li B，et al.A meta-analysis of the safety and efficacy of bosentan therapy combined with prostacyclin analogues or phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension[J].Exp Ther Med，2019，18（6）：4740-4746.
[21]	Sitbon O，Cottin V，Canuet M，et al.Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension[J].Eur Respir J，2020，56（3）：2 000 673.
[22]	Hussain A，Bennett RT，Tahir Z，et al.Differential effects of atrial and brain natriuretic peptides on human pulmonary artery：An in vitro study[J].World J Cardiol，2019，11（10）：236-243.
[23]	Schiffner R，Nistor M，Bischoff SJ，et al.Effects of human relaxin-2（serelaxin）on hypoxic pulmonary vasoconstriction during acute hypoxia in a sheep model[J].Hypoxia，2018，6：11-22.
[24]	Hood KY，Mair KM，Harvey AP，et al.Serotonin Signaling Through the 5-HT 1B Receptor and NADPH Oxidase 1 in Pulmonary Arterial Hypertension[J].Arterioscler Thromb Vasc Biol，2017，37（7）：1361-1370.
[25]	Rieg AD，Bünting NA，Cranen C，et al.Tyrosine kinase inhibitors relax pulmonary arteries in human and murine precision-cut lung slices[J].Respir Res，2019，20（1）：111.
[26]	Toya T，Nagatomo Y，Kagami K，et al.Computed tomography-measured pulmonary artery to aorta ratio and EUTOS score for detecting dasatinib-induced pulmonary arterial hypertension[J].Int J Cardiovasc Imaging，2019，35（8）：1435-1442.
[27]	Ruan H，Zhang Y，Liu R，et al.The acute effects of 30 mg vs 60 mg of intravenous Fasudil on patients with congenital heart defects and severe pulmonary arterial hypertension[J].Congenit Heart Dis，2019，14（4）：645-650.
[28]	Siddique MAH，Satoh K，Kurosawa R，et al.Identification of Emetine as a Therapeutic Agent for Pulmonary Arterial Hypertension Novel Effects of an Old Drug[J].Arterioscler Thromb Vasc Biol，2019，39（11）：2367-2385.
[29]	Kimura G，Kataoka M，Inami T，et al.Sorafenib as a potential strategy for refractory pulmonary arterial hypertension[J].Pulm Pharmacol Ther，2017，44：46-49.
[30]	Xue C，Senchanthisai S，Sowden M，et al.Endothelial-to-Mesenchymal Transition and Inflammation Play Key Roles in Cyclophilin A-Induced Pulmonary Arterial Hypertension[J].Hypertension，2020，76（4）：1113-1123.
[31]	Lichtblau M，Furian M，Aeschbacher SS，et al.Dexamethasone improves pulmonary hemodynamics in COPD-patients going to altitude：A randomized trial[J].Int J Cardiol Heart Vasc，2019，283：159-164.
[32]	Feng W，Hu Y，An N，et al.Alginate Oligosaccharide Alleviates Monocrotaline-Induced Pulmonary Hypertension via Anti-Oxidant and Anti-Inflammation Pathways in Rats[J].Int Heart J，2020，61（1）：160-168.
[33]	Zhang J，Lu X，Liu M，et al.Melatonin inhibits inflammasome-associated activation of endothelium and macrophages attenuating pulmonary arterial hypertension[J].Cardiovasc Res，2020，116（13）：2156-2169.
[34]	Tu L，Desroches-Castan A，Mallet C，et al.Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension[J].Circ Res，2019，124（6）：846-855.
[35]	Xiao Y，Peng H，Hong C，et al.DGF promotes the Warburg effect in pulmonary arterial smooth muscle cells via activation of the PI3K/AKT/mTOR/HIF-1α signaling pathway[J].Cell Physiol Biochem，2017，42（4）：1603-1613.
[36]	Meloche J，Pflieger A，Vaillancourt M，et al.Role for DNA damage signaling in pulmonary arterial hypertension[J].Circulation.2014，129（7）：786-797.
[37]	Zhang Y，Chen Y，Chen G，et al.Upregulation of miR-361-3p suppresses serotonin-induced proliferation in human pulmonary artery smooth muscle cells by targeting SERT[J].Cell Mol Biol Lett，2020，25：45.
[38]	Lei S，Peng F，Li ML，et al.LncRNA-SMILR modulates RhoA/ROCK signaling by targeting miR-141 to regulate vascular remodeling in pulmonary arterial hypertension[J].Am J Physiol Heart Circ Physiol，2020，319（2）：H377-H391.